Target intelligence / Profile preview

Alpha-1 adrenergic receptor family (ADRA1)

Target
ADRA1
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

The alpha-1 adrenergic receptor family consists of three highly homologous G protein-coupled receptor subtypes: alpha-1A, alpha-1B, and alpha-1D. These receptors are primarily coupled to the Gq/11 heterotrimeric G protein, and their activation by endogenous catecholamines (norepinephrine and epinephrine) stimulates the phospholipase C pathway, leading to intracellular calcium mobilization and subsequent smooth muscle contraction. They are widely distributed throughout the body, with high expression in vascular smooth muscle, the prostate, and the bladder neck. Consequently, they play a critical role in cardiovascular homeostasis by regulating blood pressure through vasoconstriction, as well as in the regulation of urinary flow. Therapeutically, alpha-1 adrenergic receptor antagonists (alpha-blockers) are widely used to treat benign prostatic hyperplasia by relaxing prostatic smooth muscle, and to manage hypertension by inducing vasodilation. Conversely, alpha-1 agonists are utilized as vasopressors to treat hypotension and shock, and as nasal decongestants.

Other names
Alpha-1 adrenoceptor familyAlpha-1 adrenergic receptorsAdrenergic alpha-1 receptor familyADRA1α1-adrenoceptorsα1-ARs
02

Mechanism of action

Drugs targeting the alpha-1 adrenergic receptor family act either as agonists or antagonists. Agonists (such as phenylephrine and midodrine) bind to and activate the receptors, which are coupled to Gq proteins. This activation stimulates phospholipase C (PLC), leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), which increases intracellular calcium levels and causes smooth muscle contraction (vasoconstriction). Antagonists (such as doxazosin and tamsulosin) block the binding of endogenous catecholamines (norepinephrine and epinephrine) to these receptors, preventing Gq-mediated signaling, which results in smooth muscle relaxation, vasodilation, and decreased peripheral resistance.

03

Biological functions

Signal transductionVasoconstrictionSmooth muscle contractionGlycogenolysisMydriasis
04

Disease associations

Cardiovascular diseaseHypertensionBenign prostatic hyperplasiaNasal congestionShockPost-traumatic stress disorder
05

Safety considerations

Orthostatic hypotensionFirst-dose syncopeDizzinessReflex tachycardiaNasal congestionRetrograde ejaculationIntraoperative floppy iris syndrome
06

Interacting drugs

12 more in the full profile.

07

Biomarkers

Blood pressureUrinary flow rateIntracellular calcium levels

Beyond the preview

Go deeper on Alpha-1 adrenergic receptor family (ADRA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-1 adrenergic receptor family (ADRA1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call